FENC
HEALTHCAREFennec Pharmaceuticals Inc
$7.18+0.46 (+6.85%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving FENC Today?
No stock-specific AI insight has been generated for FENC yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$5.65$9.92
$7.18
Fundamentals
Market Cap$249M
P/E Ratio—
EPS$-0.34
Dividend Yield—
Dividend / Share—
ROE-0.7%
Profit Margin-0.2%
Debt / Equity—
Trading
Volume241K
Avg Volume (10D)—
Shares Outstanding34.7M
FENC News
20 articles- Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Lags Revenue EstimatesYahoo Finance·May 7, 2026
- Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026Yahoo Finance·May 7, 2026
- Fennec Pharmaceuticals Announces Acceptance of Abstracts at the 2026 ASCO Annual MeetingYahoo Finance·Apr 21, 2026
- Wedbush Refines Fennec Pharmaceuticals Estimates Ahead of Q1 EarningsYahoo Finance·Apr 16, 2026
- Fennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer CenterYahoo Finance·Apr 7, 2026
- Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Mar 31, 2026
- Companies Like Fennec Pharmaceuticals (NASDAQ:FENC) Can Afford To Invest In GrowthYahoo Finance·Mar 26, 2026
- Fennec Pharmaceuticals Inc. Q4 2025 Earnings Call SummaryMoby·Mar 25, 2026
- Fennec Pharmaceuticals Inc (FENC) Q4 2025 Earnings Call Highlights: Record Sales and Strategic ...Yahoo Finance·Mar 24, 2026
- Adherex Technologies Q4 Earnings Call HighlightsMarketbeat·Mar 24, 2026
- Adherex Technologies Inc. (FENC) Reports Q4 Loss, Misses Revenue EstimatesYahoo Finance·Mar 24, 2026
- Fennec Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateYahoo Finance·Mar 24, 2026
- Pelthos Therapeutics Inc. (PTHS) Reports Q4 Loss, Tops Revenue EstimatesYahoo Finance·Mar 19, 2026
- Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026Yahoo Finance·Mar 18, 2026
- Gossamer Bio (GOSS) Reports Q4 Loss, Beats Revenue EstimatesYahoo Finance·Mar 17, 2026
- B Riley Reaffirms Fennec's Buy Rating, US$16.00 Price Target After Cipla SettlementYahoo Finance·Mar 17, 2026
- Sector Update: Health Care Stocks Advance Late AfternoonYahoo Finance·Mar 16, 2026
- Fennec Pharmaceuticals Announces Settlement Agreement Resolving PEDMARK Patent LitigationYahoo Finance·Mar 16, 2026
- Water Giant With $7 Billion in Revenue Draws $7.5 Million Investment, and Shares Are Surging This YearMotley Fool·Mar 15, 2026
- Payments Stock Down 30% Draws $6 Million Bet as Company Posts $4 Billion in RevenueMotley Fool·Mar 15, 2026
All 20 articles loaded
Price Data
Open$6.80
Previous Close$6.72
Day High$7.26
Day Low$6.61
52 Week High$9.92
52 Week Low$5.65
52-Week Range
$5.65$9.92
$7.18
Fundamentals
Market Cap$249M
P/E Ratio—
EPS$-0.34
Dividend Yield—
Dividend / Share—
ROE-0.7%
Profit Margin-0.2%
Debt / Equity—
Trading
Volume241K
Avg Volume (10D)—
Shares Outstanding34.7M
About Fennec Pharmaceuticals Inc
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops candidate products for use in the treatment of cancer in the United States. The company is headquartered in Research Triangle Park, North Carolina.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—